Search academic texts

Information × Registration Number 0221U103505, (0120U102578) , R & D reports Title Diagnosis and approaches to medical correction of manifestations of heart failure in patients with coronary heart disease after myocardial revascularization. popup.stage_title Вивчення ступеню деформаційних порушень міокарду та маркерів фіброзу у пацієнтів ІХС перед аортокоронарним шунтуванням Head Molodan Oleksandr V., Кандидат медичних наук Registration Date 21-02-2021 Organization State Institution “Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine” popup.description1 Develop a comprehensive approach to the diagnosis and clinical effectiveness of drug correction of manifestations of heart failure in patients with coronary heart disease (CHD) after myocardial revascularization using analysis of left ventricular myocardial deformation properties and study the dynamics of ST2 level. popup.description2  In recent decades, a large number of experimental and clinical studies have been aimed at studying the pathogenesis, improving the effectiveness of treatment and developing new methods of coronary heart disease prevention. The scientific concept of CVD prevention is the concept of risk factors (RF), which means factors associated with the development and progression of the disease [Gurevich B.C. 2008]. At present, promising opportunities for the application of biomarker strategy for early personalized diagnosis of cardiovascular pathology are being actively studied [Berezin A.E.2016;]. However, to better understand the interaction of neurohumoral and biomechanical mechanisms in CHF, it is necessary to evaluate additional markers that reflect other pathophysiological pathways, such as heart remodeling and fibrosis [Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H. et al. 2013., Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C. et al.2008;]. The use of new biomarkers seems promising, and in this sense is actively looking for the "ideal" biomarker that can characterize the activation of all parts of the CHF syndrome [Bayes-Genis A., de Antonio M., Vila J., Peñafiel J., Galán A., Barallat J. et al. 2014, Ciccone MM, Cortese F., Gesualdo M., Riccardi R., Di Nunzio D., Moncelli M., Iacoviello M., Scicchitano P. 2013]. Recently, a large number of biomarkers have been studied, and one of the most promising of them is the growth factor ST2. ST2 (growth stimulating factor expressed by genome 2, also known as IL1RL1) is a member of the interleukin-1 (IL-1) family of receptors. Elevated concentrations of circulating ST2 in the blood indicate a high risk of adverse effects, hospitalization [Memon A.A., Sundquist K., Pirouzi Fard M. et al. 2018]. The data obtained in relation to ST2 as a marker of adverse CCC in coronary heart disease, are contradictory and they are clearly insufficient, and therefore it is necessary to conduct furth Product Description popup.authors Chmul Karyna O. popup.nrat_date 2021-02-21 Close

Information × Registration Number 0221U103505, (0120U102578) , R & D reports Title Diagnosis and approaches to medical correction of manifestations of heart failure in patients with coronary heart disease after myocardial revascularization. popup.stage_title Вивчення ступеню деформаційних порушень міокарду та маркерів фіброзу у пацієнтів ІХС перед аортокоронарним шунтуванням Head Molodan Oleksandr V., Кандидат медичних наук Registration Date 21-02-2021 Organization State Institution “Zaporizhia Medical Academy of Post-Graduate Education Ministry of Health of Ukraine” popup.description1 Develop a comprehensive approach to the diagnosis and clinical effectiveness of drug correction of manifestations of heart failure in patients with coronary heart disease (CHD) after myocardial revascularization using analysis of left ventricular myocardial deformation properties and study the dynamics of ST2 level. popup.description2  In recent decades, a large number of experimental and clinical studies have been aimed at studying the pathogenesis, improving the effectiveness of treatment and developing new methods of coronary heart disease prevention. The scientific concept of CVD prevention is the concept of risk factors (RF), which means factors associated with the development and progression of the disease [Gurevich B.C. 2008]. At present, promising opportunities for the application of biomarker strategy for early personalized diagnosis of cardiovascular pathology are being actively studied [Berezin A.E.2016;]. However, to better understand the interaction of neurohumoral and biomechanical mechanisms in CHF, it is necessary to evaluate additional markers that reflect other pathophysiological pathways, such as heart remodeling and fibrosis [Yancy C.W., Jessup M., Bozkurt B., Butler J., Casey D.E., Drazner M.H. et al. 2013., Sabatine M.S., Morrow D.A., Higgins L.J., MacGillivray C., Guo W., Bode C. et al.2008;]. The use of new biomarkers seems promising, and in this sense is actively looking for the "ideal" biomarker that can characterize the activation of all parts of the CHF syndrome [Bayes-Genis A., de Antonio M., Vila J., Peñafiel J., Galán A., Barallat J. et al. 2014, Ciccone MM, Cortese F., Gesualdo M., Riccardi R., Di Nunzio D., Moncelli M., Iacoviello M., Scicchitano P. 2013]. Recently, a large number of biomarkers have been studied, and one of the most promising of them is the growth factor ST2. ST2 (growth stimulating factor expressed by genome 2, also known as IL1RL1) is a member of the interleukin-1 (IL-1) family of receptors. Elevated concentrations of circulating ST2 in the blood indicate a high risk of adverse effects, hospitalization [Memon A.A., Sundquist K., Pirouzi Fard M. et al. 2018]. The data obtained in relation to ST2 as a marker of adverse CCC in coronary heart disease, are contradictory and they are clearly insufficient, and therefore it is necessary to conduct furth Product Description popup.authors Chmul Karyna O. popup.nrat_date 2021-02-21 Close